Pharsight

Brisdelle generic

Brisdelle is an anti-menopausal drug owned by Sebela Ireland Ltd. This drug contains the active ingredient paroxetine mesylate and was first authorized for market use on 28 June, 2013. Brisdelle, available in capsule; oral dosage forms, holds a total of 4 patents, none of which have expired.

When will Brisdelle generic be available?

Brisdelle's generics are projected to be released after 6 April, 2029. This corresponds to the expiry date of the last patent, US8658663, titled 'Method of treating thermoregulatory disfunction with paroxetine.'

Brisdelle uses

Brisdelle is used in the treatment of moderate to severe vasomotor symptoms associated with menopause. The active ingredient, paroxetine mesylate, makes this drug effective for these symptoms.

Brisdelle patent expiration

Brisdelle holds four patents, with the last one expiring on 6 April, 2029. This patent, US8658663, is titled 'Method of treating thermoregulatory disfunction with paroxetine.' Look forward to the release of Brisdelle generic after this date. Below are the details of the patents:

Litigations filed on Brisdelle

Brisdelle dosage

Want to ask something?